Skip to content
BioSupply Trends Quarterly logo
  • About Us
  • About Us
Subscribe
  • News
    • Artificial Intelligence
    • Biosimilars
    • Clinical Trials
    • COVID
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Therapeutics
    • Vaccines
    • Washington Report
  • Industry Insight
    • Artificial Intelligence
    • Biosimilars
    • Chronic Illness
    • COVID
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
  • Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • News
    • Artificial Intelligence
    • Biosimilars
    • Clinical Trials
    • COVID
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Therapeutics
    • Vaccines
    • Washington Report
  • Industry Insight
    • Artificial Intelligence
    • Biosimilars
    • Chronic Illness
    • COVID
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
  • Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Home
  • News
    • All News
    • Artificial Intelligence
    • Biosimilars
    • Clinical Trials
    • COVID
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Therapeutics
    • Vaccines
    • Washington Report
  • Industry Insight
    • All Industry Insight
    • Artificial Intelligence
    • Biosimilars
    • Chronic Illness
    • COVID
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
  • Operations & Management
    • All Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • All Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Subscribe
  • About Us
  • Home
  • News
    • All News
    • Artificial Intelligence
    • Biosimilars
    • Clinical Trials
    • COVID
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Therapeutics
    • Vaccines
    • Washington Report
  • Industry Insight
    • All Industry Insight
    • Artificial Intelligence
    • Biosimilars
    • Chronic Illness
    • COVID
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
  • Operations & Management
    • All Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • All Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Subscribe
  • About Us
BioSupply Trends Quarterly logo

Category: News

Finalized Rule Gives Patients More Control Over Their Health Data

Illustration of healthcare coordination

In March, the U.S. Department of Health and Human Services (HHS) finalized two rules that give patients unprecedented safe and secure access to their health data.

Coronavirus Relief Funds to Pay for Care for Uninsured

illustration of a virus

The U.S. Department of Health and Human Services (HHS) is using a $100 billion hospital and provider relief fund to pay hospitals at Medicare rates for uncompensated COVID-19 care for uninsured individuals.

FcRn Antagonist Boosts Platelet Counts, Reduces Bleeding Risk in Patients with Immune Thrombocytopenic Purpura

Illustration of blood cells

Efgartigimod, an investigational human IgG1 Fc fragment, induced a rapid reduction in total IgG levels and clinically relevant increases in platelet counts in patients with primary immune thrombocytopenia (ITP), according to findings from a Phase II, placebo-controlled multinational study.

High-Titer Inhibitors Reduced in PUPs with Severe Hemophilia A Treated with Fourth Generation Recombinant Factor VIII

Image of felt board with "hemophilia" on it

A study in previously untreated patients (PUPs) with severe hemophilia A found replacement therapy with a fourth-generation recombinant factor VIII (FVIII) product was associated with an incidence of high-titer inhibitors similar to the rate seen in a landmark trial evaluating plasma-derived FVIII products.

CDC Analyses Show Flu Vaccine Reduces Risk of Hospitalization in Children and Death in Adults

Image of paperdolls and syringe

Two analyses by the Centers for Disease Control and Prevention (CDC) show the influenza (flu) vaccine can reduce the likelihood of hospitalization in children and death in adults.

Trivalent HBV Vaccine Superior in Efficacy in Adults 45 Years and Older

Photo of HBV vaccine

A Phase III study has found a trivalent hepatitis B virus (HBV) vaccine demonstrated superiority in adults 45 years and older and noninferior in adults older than 18 years compared with a monovalent vaccine.

Study Finds Safe Treatment for Children with Severe Hemophilia A with Inhibitors

Photo of researcher handling blood vials

Researchers have found combining immune tolerance induction (ITI) with Hemlibra (emicizumab, Roche) is a feasible and safe way of treating children with severe hemophilia A.

Flu Vaccine May Reduce Risk of Heart Attack and Stroke in Hypertensive Individuals

Photo of researcher looking at an image of a patient

A new study shows cardiovascular outcomes may improve in individuals with hypertension if they receive the influenza (flu) vaccine during the flu season.

Skin Patch Shows Promise for Delivery of Influenza Vaccine

Vaccine patch

Researchers at the University of Rochester Medical Center in New York City have developed a new type of skin patch that could replace needles as a method to deliver the influenza (flu) vaccine.

FDA Expands Indication for Octapharma’s WILATE to Hemophilia A

Photo of researcher and blood vial

The U.S. Food and Drug Administration (FDA) has approved WILATE for treatment of adults and adolescents with hemophilia A for routine prophylaxis.

← Previous
Next →
BioSupply Trends Quarterly logo
FFF Enterprises logo
  • Current Issue
  • Past Issues
  • Resources
  • Current Issue
  • Past Issues
  • Resources
  • About BSTQ
  • Subscribe to BSTQ
  • eNewsletter Opt-in
  • Contact Us
  • About BSTQ
  • Subscribe to BSTQ
  • eNewsletter Opt-in
  • Contact Us
  • Advertiser Information
  • Media Kit
  • Editorial Calendar
  • Editorial Guidelines
  • Advertiser Information
  • Media Kit
  • Editorial Calendar
  • Editorial Guidelines
Facebook-f Instagram Linkedin-in Youtube

FFF Enterprises.com | Privacy Statement | Terms of Use | California Consumer Privacy Act (CCPA) Opt-Out Icon

FFF Enterprises.com
Privacy Statement
Terms of Use
California Consumer Privacy Act (CCPA) Opt-Out Icon

©2024 FFF Enterprises, Inc. All Rights Reserved. Property of FFF Enterprises, Inc.

The information provided on this website is not medical advice, nor is it intended to be a substitute for medical advice, diagnosis, and treatment. Always seek the advice of a physician or other qualified health provider with questions concerning a medical condition. Never disregard professional medical advice, or delay seeking it based on information provided on this website.